Impact of Melatonin on Motor, Cognitive and Neuroimaging Indices in Patients with Multiple Sclerosis
-
Tina Roostaei
,
Mohammad Ali Sahraian
,
Sara Hajeaghaee
,
Taha Gholipour
,
Mansoureh Togha
,
Bahaadin Siroos
,
Sepideh Mansouri
,
Zahra Mohammadshirazi
,
Maryam Aghazadeh Alasti
,
Mohammad Hossein Harirchian
Abstract
A series of preclinical and clinical studies have shown the immunomodulatory effect of melatonin, especially in the state of chronic inflammation. A double-blind, randomized, parallel-group, placebo-controlled clinical trial was designed to study the tolerability and efficacy of supplemental therapy with melatonin (3 mg/day) in comparison to placebo in relapsing-remitting MS (RRMS) patients receiving once weekly interferon beta. Patients were followed up for 12 months. Primary outcomes consisted of the number of relapses, change in Extended Disability Status Scale (EDSS), and the number and volume of new T2 and gadolinium-enhancing brain lesions. Secondary outcomes included change in performance on Multiple Sclerosis Functional Composite (MSFC) as well as change in fatigue and depression. The outcomes were evaluated every three months. Twenty-six patients (13 in each group) were recruited in the study. All participants, except for one patient in the placebo group, completed the study. No patient reported serious adverse events. There was no significant difference either in primary or secondary outcomes between melatonin and placebo arm. However, a trend for beneficial effect was observed for melatonin on change in MSFC performance and the cognitive subscore of the Modified Fatigue Impact Scale (p=0.05 and 0.006, respectively, not corrected for multiple comparisons). We found no significant effect for treatment with melatonin on measures of clinical and functional disability and development of brain lesions in our small sample-size study. Studies with higher statistical power and longer follow up are needed to further evaluate the potential immunomodulatory effect of melatonin in RRMS treatment.
1. Axelrod J, Weissbach H. Enzymatic o-methylation of n- acetylserotonin to melatonin. Science 1960;131(3409):1312.
2. Zawilska JB, Skene DJ, Arendt J. Physiology and pharmacology of melatonin in relation to biological rhythms. Pharmacol Rep 2009; 61(3):383–410.
3. Richter HG, Torres-Farfan C, Garcia-Sesnich J, Abarzua- Catalan L, Henriquez MG, Alvarez-Felmer M, et al. Rhythmic expression of functional MT1 melatonin receptors in the rat adrenal gland. Endocrinology 2008;149(3):995-1003.
4. Maestroni GJ, Conti A. Immuno-derived opioids as mediators of the immuno-enhancing and anti-stress action of melatonin. Acta Neurol (Napoli) 1991; 13(4):356-60.
5. Orbach H, Shoenfeld Y. Hyperprolactinemia and autoimmune diseases. Autoimmun Rev 2007;6(8):537-42.
6. Rajaratnam SM, Arendt J. Health in a 24-h society.Lancet 2001; 358(9286):999–1005.
7. Radogna F, Diederich M, Ghibelli L. Melatonin: A pleiotropic molecule regulating inflammation. Biochem. Pharmacol 2010; 80(12):1844–52.
8. Whitacre CC, Dowdell K, Griffin AC. Neuroendocrine influences on experimental autoimmune encephalomyelitis. Ann N Y Acad Sci 1998; 840:705-16.
9. Nelson RJ, Demas GE. Role of melatonin in mediating seasonal energetic and immunologic adaptations. Brain Res Bull 1997; 44(4):423-30.
10. Rudick RA, Cutter G, Baier M, Fisher E, Dougherty D, Weinstock-Guttman B, et al. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. Neurology 2001; 56(10):1324-30.
11. Carrillo-Vico A, Lardone PJ, Alvarez-Sánchez N, Rodríguez-Rodríguez A, Guerrero JM. Melatonin: buffering the immune system. Int J Mol Sci 2013;14(4):8638-83.
12. Lissoni P, Rovelli F, Meregalli S, Fumagalli L, Musco F, Brivio F, et al. Melatonin as a new possible anti- inflammatory agent. J Biol Regul Homeost Agents 1997;11(4):157-9.
13. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58(6):840-6.
14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis an expanded disability status scale (EDSS). Neurology 1983; 33(11):1444-52.
15. Eshaghi A, Riyahi-Alam S, Roostaei T, Haeri G, Aghsaei A, Aidi MR, et al. Validity and reliability of a Persian translation of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS). Clin Neuropsychol 2012; 26(6):975-84.
16. Harirchian MH, Nasergivechi S, Maddah M, Meysamie A, Amini H, Shandiz EE, et al. Evaluation of the Persian version of modified fatigue impact scale in Iranian patients with multiple sclerosis. Iran J Neurol 2013;12(1):32.
17. Ghassemzadeh H, Mojtabai R, Karamghadiri N, Ebrahimkhani N. Psychometric properties of a Persian- language version of the Beck Depression Inventory- Second edition: BDI-II-PERSIAN. Depress Anxiety 2005; 21(4):185-92.
18. Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage.2002; 17(2):825-41.
19. Smith SM, Brady JM. SUSAN .A new approach to low level image processing. International journal of computer vision 1997; 23(1):45-78.
20. Hardeland R, Madrid JA, Tan DX, Reiter RJ. Melatonin, the circadian multioscillator system and health: The need for detailed analyses of peripheral melatonin signaling. J Pineal Res 2012; 52(2):139–66.
21. Garcia-Maurino S, Gonzalez-Haba MG, Calvo JR, Rafii- El-Idrissi M, Sanchez-Margalet V, Goberna R, et al. Melatonin enhances IL-2, IL-6, and IFN-gamma production by human circulating CD4+ cells: a possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes. J Immunol 1997;159(2):574-81.
22. Pioli C, Caroleo MC, Nistico G, Doria G. Melatonin increases antigen presentation and amplifies specific and non specific signals for T-cell proliferation. Int J Immunopharmacol 1993; 15(4):463-8.
23. Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. Endocrine 2005; 27(2):189-200.
24. Melamud L, Golan D, Luboshitzky R, Lavi I, Miller A.Melatonin dysregulation, sleep disturbances and fatigue in multiple sclerosis. J Neurol Sci 2012; 314(1-2):37–40.
25. Sandyk R. Influence of the pineal gland on the expression of experimental allergic encephalomyelitis: possible relationship to the aquisition of multiple sclerosis. Int J Neurosci 1997; 90(1-2):129-33.
26. Jankovic BD, Isakovic K, Petrovic S. Effect of pinealectomy on immune reactions in the rat. Immunology 1970; 18(1):1-6.
27. Gholipour T , Ghazizadeh T, Babapour S, Mansouri B, Ghaffarpour M, Siroos B, et al. Decreased Urinary Level of Melatonin as a Marker of Disease Severity in Patients with Multiple Sclerosis. Iran J Allergy Asthma Immunol 2015; 14(1):91-7.
28. Adamczyk-Sowa M, Pierzchala K, Sowa P, Mucha S, Sadowska-Bartosz I, Adamczyk J, et al. Melatonin Acts as Antioxidant and Improves Sleep in MS Patients. Neurochem Res 2014; 39(8):1585-93.
29. Adamczyk-Sowa M, Pierzchala K, Sowa P, Polaniak R, Kukla M, Hartel M. Influence of melatonin supplementation on serum antioxidative properties and impact of the quality of life in multiple sclerosis patients. J Physiol Pharmacol 2014; 65(4):543-50.
30. Bahamonde C, Conde C, Agüera E, Lillo R, Luque E, Gascón F, et al. Elevated melatonin levels in natalizumab-treated female patients with relapsing- remitting multiple sclerosis: Relationship to oxidative stress. Eur J Pharmacol 2014; 730:26-30.
| Files | ||
| Issue | Vol 14, No 6 (2015) | |
| Section | Original Article(s) | |
| Keywords | ||
| Immunomodulation Melatonin Multiple sclerosis | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
